SuperworthUnitedHealth UNH
- Market cap
- $375.3B
- PE
- 23.9×
- 10y median 22.7×
- Forward PE
- 18.5×
- 10y median 19.5×
- Price to sales
- 0.8×
- EV/EBIT
- 17.5×
- Revenue, 12 months
- $449.7B
- +3% on a year ago
- Net margin
- 3.5%
- Free cash flow yield
- n/m
- Q3 FY26 missing
UnitedHealth trades at 23.9× trailing earnings, near its ten-year median. Revenue was $449.7B over the last twelve months, up 3% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $94.4B+14% | $99.8B+9% | $98.9B+6% | $100.8B+9% | $100.8B+7% | $109.6B+10% | $111.6B+13% | $113.2B+12% | $113.2B+12% | $111.7B+2% | $112B+0% | $112.7B−0% | |
| Cost of revenue | $10.2B+23% | $11.1B+18% | $11.3B+16% | $11.8B+26% | $12.5B+22% | $12.4B+12% | $13B+15% | $12.6B+6% | $12.7B+2% | $12.8B+4% | $13.4B+3% | n/a |
| SG&A | $13.3B+3% | $14.1B+3% | $13.2B−5% | $13.3B−4% | $12.5B−6% | $13.6B−3% | $13.8B+5% | $15.2B+15% | $17B+36% | $15.4B+13% | $14.3B+4% | $14.4B−6% |
| $7.7B+12% | $7.9B−2% | $7.9B−2% | $8.7B+2% | $7.8B+1% | $9.1B+15% | $5.2B−35% | $4.3B−50% | $380M−95% | $9B−1% | $8B+55% | $6.6B+52% | |
| Interest expense | $830M+23% | $844M+12% | $985M+19% | $1.1B+29% | $1B+21% | $998M+18% | $1B+4% | $1B−7% | $974M−3% | $955M−4% | $962M−6% | n/a |
| Pre-tax income | $6.9B+10% | $1M−100% | $5.7B−22% | $7.6B−1% | $6.8B−1% | $8.1B+810500% | $4.1B−28% | $3.2B−58% | −$720M | $8B−2% | $7B+71% | $5.5B+71% |
| $1.2B−9% | $1.2B−22% | $1.2B−21% | $1.4B−18% | $1B−15% | $1.6B+34% | $510M−59% | $686M−49% | −$938M | $1.5B−9% | $1.3B+155% | $1.2B+78% | |
| Net income | $5.5B+15% | −$1.4B | $4.2B−23% | $6.1B+4% | $5.5B+2% | $6.3B | $3.4B−19% | $2.3B−61% | $10M−100% | $6.3B−0% | $5.5B+61% | $4.1B+75% |
| $5.83+16% | −$1.53 | $4.54−22% | $6.51+4% | $5.98+3% | $6.85 | $3.74−18% | $2.59−60% | $0.01−100% | $6.90+1% | $6.04+62% | $4.56+76% | |
| 935M−1% | 922M−2% | 928M−1% | 930M−1% | 927M−1% | 918M−0% | 910M−2% | 908M−2% | 910M−2% | 910M−1% | 906M−0% | n/a |
Net income: 12 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY08 and Q4 FY16: quarter's net income to common over its shares, to the cent. 12 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 6 periods, Q4 FY08 to Q4 FY16: share-days: the 12-month average less the 9-month, weighted by days. 12 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $112.2B | $108.5B to $115.4B | $2.28 | $2.19 to $2.53 | 15 |
| Q1 FY27 | $113.5B | $110.9B to $116.7B | $8.15 | $6.69 to $8.77 | 12 |
| Q2 FY27 | $115.3B | $111.9B to $118.8B | $6.91 | $6.64 to $7.18 | 5 |
| Q3 FY27 | $116.5B | $113B to $120B | $5.30 | $5.09 to $5.50 | 5 |
| Q4 FY27 | $117.6B | $114.1B to $121.1B | $3.08 | $2.96 to $3.19 | 5 |
| Q1 FY28 | $120.2B | $116.6B to $123.8B | $9.18 | $8.82 to $9.54 | 6 |
| Q2 FY28 | $122.2B | $118.6B to $125.9B | $7.96 | $7.65 to $8.26 | 6 |
| Q3 FY28 | $123B | $119.3B to $126.6B | $6.45 | $6.19 to $6.69 | 6 |
Peers
Companies in Medical - Healthcare Plans nearest UnitedHealth's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| UNHUnitedHealth | $375.3B | 23.9× | 22.7× | 18.5× | 0.8× | +3% | 3.5% |
| CVSCVS Health | $119.5B | 24.7× | 16.2× | 11.5× | 0.3× | +7% | 1.2% |
| ELVElevance Health | $95.4B | 19.6× | 17.6× | 16.1× | 0.5× | +6% | 2.5% |
| CICigna | $81.1B | 12.7× | 16.1× | 9.7× | 0.3× | +8% | 2.3% |
| HUMHumana | $50.7B | 39.9× | 20.7× | 33.7× | 0.3× | +18% | 0.9% |
| Peer median | $88.3B | 22.1× | 16.9× | 13.8× | 0.3× | +8% | 1.7% |
Investors who own it
Investors we follow who held UnitedHealth at the end of Jun 30, 2026, from their 13F filings.
- Ruane, Cunniff & GoldfarbRuane, Cunniff & Goldfarb (Sequoia Fund)4.6% of portfoliotrimmed
- Chase ColemanTiger Global Management0.5% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfolionew
More on UnitedHealth
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 11Health insurers with the highest profit margins
- #10of 33Healthcare stocks with the highest dividend yields
- #6of 10Health insurers with the lowest EV/EBIT
- #9of 11Health insurers with the lowest price to sales ratio
- #10of 11Health insurers with the fastest revenue growth
Its groups
About
- Chief executive
- Stephen Hemsley, since 2025Returned as CEO in May 2025 after leading from 2006 to 2017. Source
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .